Latest Market Entry News

Neuren Pharmaceuticals reports a 16% rise in Q2 2025 royalties driven by Acadia’s DAYBUE sales growth and expanding patient base in the US. Full-year sales guidance remains strong with European market entry on the horizon.

EBR Systems has won final CMS approval for New Technology Add-On Payment reimbursement, paving the way for Medicare coverage of its innovative WiSE cardiac pacing system starting October 2025.

HeraMED advances AI-driven maternity care partnerships and strengthens its US commercial team, navigating policy uncertainties while progressing its global expansion and funding strategies.

Rhythm Biosciences has advanced its ColoSTAT® diagnostic kits to final production validation, demonstrating consistent detection of colorectal cancer across all stages in a pivotal study. The company is gearing up for regulatory submission and commercial launch later this year.

Talga Group has begun trading on the U.S. OTCQX market, enhancing liquidity and visibility among American investors without issuing new shares. This move complements its existing listings on the ASX and Börse Frankfurt, positioning Talga for growth amid rising demand for sustainable battery materials.

SRJ Technologies has inked a US$6 million joint venture in the Middle East and launched a fully underwritten A$2.5 million entitlement offer to accelerate its regional expansion.

Ovanti Limited has appointed Peter Maher, a seasoned BNPL executive from Zip Co, to lead its US expansion, while exploring a NASDAQ listing via dual-listing or SPAC merger and reconsidering the sale of a key dividend-yielding asset.

4DMedical has landed a $10 million strategic investment from Pro Medicus, aimed at accelerating its commercial growth and advancing its CT – VQ™ technology towards FDA clearance in the US.

Vectus Biosystems confirms safety of its lead fibrosis drug VB0004 from Phase Ia/Ib trials and advances licensing talks globally, including in China, while managing costs and funding challenges.

SportsHero Limited has advanced its iGV Family Game Pass commercialization with launches in Indonesia and the Philippines, backed by new Telco partnerships and a A$1.65 million capital raise.

Provaris Energy has marked significant milestones in Q2 2025 with a key MOU with global shipping leader 'K' LINE and a joint venture formation with Yinson to commercialise proprietary hydrogen and carbon dioxide transport technologies.

Tissue Repair Limited reports steady progress in its Phase 3 clinical trials for TR987® despite patient recruitment hurdles, while TR Pro+® sales surge and new distribution deals pave the way for international growth.